Chapter 69: Disorders of Phosphate Homeostasis

Slides:



Advertisements
Similar presentations
TmP/GFR = maximum reabsorption of PO4 per unit volume of GFR
Advertisements

Chapter 2 Skeletal system. Anatomy and physiology Skeletal system composed of 206 separate bones. Bone is a type of connective tissue its matrix consists.
A Diagnostic Testing Service for Hypophosphatemic Rickets
X-Linked hypophosphatemic rickets (XLH), caused by mutations in PHEX, is the most common inherited disorder of renal phosphate wasting. The PHEX mutation.
Chapter 16 Chapter 16 Phosphatonins Copyright © 2013 Elsevier Inc. All rights reserved.
X-LINKED HYPOPHOSPHATEMIA Tom Gillespie Rinzin Dorjee Martin Kutti.
Chapter 105: Craniofacial Disorders Affecting the Dentition: Genetic Yong-Hee Chun, Paul H. Krebsbach, and James P. Simmer.
Chapter 83: Bone Cancer and Pain Mary Ann C. Sabino and Denis R. Clohisy.
Non Inflammatory Pathology of Bone &Joints Non Inflammatory Pathology of Bone &Joints By By Dr. Atif Ali.
내분비 대사 내과 전임의 이윤정 Hypophosphatemic & Osteomalacia disorders – FGF 23(Fibroblast Growth Factor 23)
Chapter 93: Vascular Calcification Dwight A. Towler and Linda L. Demer.
TUMOUR HISTOLOGY SERUM BIOCHEMISTRY miRNA PROFILE TUMOUR RADIOLOGY FURTHER WORK & CLINICAL APPLICATION SMALL RNA LIBRARY CONSTRUCTION MOLECULAR BIOLOGY.
Daniel Bikle, John Adams, and Sylvia Christakos
Chapter 107: Bisphosphonate-Associated Osteonecrosis of the Jaws Nathaniel S. Treister and Sook-Bin Woo.
Chapter 75: Hypoparathyroidism and Pseudohypoparathyroidism
Chapter 85: Treatment and Prevention of Bone Metastases and Myeloma Bone Disease Jean-Jacques Body.
Chapter 32: Radionuclide Scintigraphy in Metabolic Bone Disease Gopinath Gnanasegaran, Gary J. R. Cook, and Ignac Fogelman.
RICKETS By- shahbaz ahmed.
Chapter 49: Bisphosphonates for Postmenopausal Osteoporosis
Chapter 109: Oral Manifestations of Metabolic Bone Disease
Disorders of Ca Metabolism Hypercalcaemia (BY Basil OM Saleh) OBJECTIVE: • Clinical characteristics •Biochemical.
Skeletal Physiology: Fetus and Neonate
Chapter 108: Periodontal Diseases and Oral Bone Loss
A simplified schema for the regulation of serum phosphate by PTH, 1,25(OH)2D and fibroblast growth factor 23 (FGF23). FGF23 is produced predominantly by.
Coagulation cascade:.
Chapter 62: Osteoporosis in Men
Chapter 68: Hypocalcemia: Definition, Etiology, Pathogenesis, Diagnosis, and Management Dolores Shoback.
Chapter 89: Fibrous Dysplasia
Chapter 87: Orthopedic Treatment of Metastatic Bone Disease
Chapter 38: Epidemiology of Osteoporotic Fractures
Chapter 61: Transplantation Osteoporosis
Chapter 2 Skeletal system
Chapter 71: Vitamin D– Related Disorders
Bone Metabolism MSS/Biochemistry, fall-2017
Chapter 45: Orthopedic Surgical Principles of Fracture Management
Chapter 50: Strontium Ranelate in the Prevention of Osteoporotic Fractures René Rizzoli.
Chapter 80: Hematologic Malignancies and Bone
Chapter 67: Non-Parathyroid Hypercalcemia
Chapter 10: Neuronal Regulation of Bone Remodeling
Chapter 72: Paget’s Disease of Bone
Chapter 21: Regulation of Calcium and Magnesium
Chapter 6: The Composition of Bone
Chapter 74: Disorders of Mineral Metabolism in Childhood
Chapter 15: Ethnic Differences in Bone Acquisition
Chapter 55: Cost-Effectiveness of Osteoporosis Treatment
Chapter 70: Magnesium Depletion and Hypermagnesemia
Chapter 14: Skeletal Development in Childhood and Adolescence
Chapter 60: Osteoporosis: Other Secondary Causes
Chapter 35: Bone Biopsy and Histomorphometry in Clinical Practice
Volume 67, Pages S1-S7 (June 2005)
Chapter 4: Osteocytes Lynda F. Bonewald.
Chapter 88: Sclerosing Bone Disorders
Chapter 94: Fibrodysplasia (Myositis) Ossificans Progressiva
Electrolyte Disorders Associated With Cancer
Volume 73, Issue 1, Pages 3-5 (January 2008)
Chemical Composition of Bone: Organic
X-linked Hypophosphatemic Rickets and its Treatment with Anti-FGF23
FGF23–parathyroid interaction: implications in chronic kidney disease
Volume 76, Issue 3, Pages (August 2009)
Evolving Gene Therapy in Primary Immunodeficiency
Volume 79, Pages S24-S27 (April 2011)
Volume 25, Issue 5, Pages (May 2017)
Volume 79, Pages S20-S23 (April 2011)
Volume 25, Issue 5, Pages (May 2017)
Volume 71, Issue 8, Pages (April 2007)
The emerging role of phosphate in vascular calcification
Protein nutrition as therapy for a genetic disorder of bone?
PHEX gene and hypophosphatemia
Tamara Isakova, Orlando M. Gutiérrez, Myles Wolf  Kidney International 
Untangling Klotho's Role in Calcium Homeostasis
Presentation transcript:

Chapter 69: Disorders of Phosphate Homeostasis Mary D. Ruppe and Suzanne M. Jan de Beur

Table 1. Clinical Consequences of Hypophosphatemia From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th Edition. www.asbmrprimer.org Table 1. Clinical Consequences of Hypophosphatemia © 2008 American Society for Bone and Mineral Research

Table 2. Causes of Hypophosphatemia From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th Edition. www.asbmrprimer.org Table 2. Causes of Hypophosphatemia © 2008 American Society for Bone and Mineral Research

Table 3. Characteristics of Renal Phosphate Wasting Disorders From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th Edition. www.asbmrprimer.org Table 3. Characteristics of Renal Phosphate Wasting Disorders © 2008 American Society for Bone and Mineral Research

Table 4. Causes of Hyperphosphatemia From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th Edition. www.asbmrprimer.org Table 4. Causes of Hyperphosphatemia © 2008 American Society for Bone and Mineral Research

From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th Edition. www.asbmrprimer.org Figure 1 Figure 1 Molecular mechanisms of disorders of phosphate homeostasis. Three major mechanisms of hypophosphatemia are FGF23 excess caused by ectopic production as in TIO, excess bone production seen in XLH, ARHR, ADHR, FD, and OGD, and mutation in the FGF23 gene that renders the protein resistant to inactivation. Hypophosphatemia may also be secondary to excess KLOTHO, the co-factor necessary for FGF23 signaling as seen in a patient with hypophosphatemic rickets with hyperparathyroidism. Finally, homozygous inactivating mutations in SLC34A3, which encodes NaPiIIc, or dominant negative mutations in SLC34A2 that encodes NaPiIIa result in phosphate wasting caused by the absence of sodium-phosphate co-transporters. Hyperphosphatemia is caused by FGF23 deficiency, either through inactivating mutations in FGF23, aberrant glycosylation of FGF23 caused by GALNT3 mutations, or FGF23 resistance caused by inactivating KLOTHO mutations. Figure 1 Molecular mechanisms of disorders of phosphate homeostasis. Three major mechanisms of hypophosphatemia are FGF23 excess caused by ectopic production as in TIO, excess bone production seen in XLH, ARHR, ADHR, FD, and OGD, and mutation in the FGF23 gene that renders the protein resistant to inactivation. Hypophosphatemia may also be secondary to excess KLOTHO, the co-factor necessary for FGF23 signaling as seen in a patient with hypophosphatemic rickets with hyperparathyroidism. Finally, homozygous inactivating mutations in SLC34A3, which encodes NaPiIIc, or dominant negative mutations in SLC34A2 that encodes NaPiIIa result in phosphate wasting caused by the absence of sodium-phosphate co-transporters. Hyperphosphatemia is caused by FGF23 deficiency, either through inactivating mutations in FGF23, aberrant glycosylation of FGF23 caused by GALNT3 mutations, or FGF23 resistance caused by inactivating KLOTHO mutations. © 2008 American Society for Bone and Mineral Research

From the Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th Edition. www.asbmrprimer.org Figure 2 Figure 2 Radiographic and histologic features in TIO. (A) Octreotide scan showing small mesenchymal tumor in the head of the humerus. (B) Hemiangiopericytoma with with numerous pericytes and vascular channels (H&E strain). (C) Bone biopsy with Goldner stain. Excessive osteoid or unmineralized bone matrix composed mainly of collagen stains pink. Minerlized bone stains blue. This bone biopsy shows severe osteomalacia. Figure 2 Radiographic and histologic features in TIO. (A) Octreotide scan showing small mesenchymal tumor in the head of the humerus. (B) Hemiangiopericytoma with with numerous pericytes and vascular channels (H&E strain). (C) Bone biopsy with Goldner stain. Excessive osteoid or unmineralized bone matrix composed mainly of collagen stains pink. Minerlized bone stains blue. This bone biopsy shows severe osteomalacia. © 2008 American Society for Bone and Mineral Research